Adverum Biotechnologies Inc ADVM:NASDAQ

Last Price$1.76NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.75 (317)
Ask (Size)$1.79 (3)
Day Low / HighN/A - N/A
Volume1.0 M
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Adverum Biotechnologies Inc ( NASDAQ )

Price: $1.76
Change: -0.08 (4.35%)
Volume: 1.0 M
4:00PM ET 12/03/2021
 
 

Ardelyx Inc ( NASDAQ )

Price: $1.52
Change: -0.18 (10.59%)
Volume: 146.6 M
4:00PM ET 12/03/2021
 
 

Larimar Therapeutics Inc ( NASDAQ )

Price: $9.59
Change: +0.01 (0.10%)
Volume: 76.7 K
4:00PM ET 12/03/2021
 
 

Seelos Therapeutics Inc ( NASDAQ )

Price: $1.64
Change: -0.10 (5.75%)
Volume: 5.5 M
4:00PM ET 12/03/2021
 
 

AquaBounty Technologies Inc ( NASDAQ )

Price: $2.36
Change: -0.21 (8.17%)
Volume: 1.2 M
4:00PM ET 12/03/2021
 

Read more news Recent News

Insider Sell: Adverum Biotechnologies
5:00PM ET 11/17/2021 MT Newswires

James Paul Scopa, Director, on November 15, 2021, sold 50,000 shares in Adverum Biotechnologies (ADVM) for $109,000. Following the Form 4 filing with the...

-- Earnings Flash (ADVM) ADVERUM BIOTECHNOLOGIES Posts Q3 Loss $-0.39
4:30PM ET 11/04/2021 MT Newswires

...

--Goldman Sachs Downgrades Adverum Biotechnologies to Neutral From Buy, Adjusts PT to $3 From $10
11:48AM ET 7/23/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Chardan Adjusts Price Target on Adverum Biotechnologies to $3 From $5 After Eye Drug Cancellation, Maintains Neutral Rating
11:39AM ET 7/23/2021 MT Newswires

Adverum Biotechnologies (ADVM) has an average hold rating and a price target range of $2 to $6, according to analysts polled by Capital IQ. (MT Newswires...

View all Commentary and Analysis

Regenxbio: Suprachoroidal Data May Impress
9:24AM ET 7/06/2021 Seeking Alpha

Regenxbio: Better Investment Case Than Adverum
8:00AM ET 5/12/2021 Seeking Alpha

Adverum Biotechnologies: An Uncertain Path Forward
11:05AM ET 5/05/2021 Seeking Alpha

Adverum Biotechnologies: One Adverse Event Too Many
7:27AM ET 5/03/2021 Seeking Alpha

Company Profile

Business DescriptionAdverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA. View company web site for more details
Address800 Saginaw Drive
Redwood City, California 94063
Phone+1.650.656.9323
Number of Employees82
Recent SEC Filing11/19/20218-K
President, CEO, Director & Chief Medical OfficerLaurent Fischer
Chief Operating OfficerPeter Soparkar
Chief Financial & Accounting OfficerJack Anthony Thrift
Senior VP & Head-Technical OperationsHeikki Jouttijärvi

Company Highlights

Price Open$1.83
Previous Close$1.84
52 Week Range$1.69 - 14.79
Market Capitalization$172.7 M
Shares Outstanding98.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.52
Beta vs. S&P 500N/A
Revenue$1.6 M
Net Profit Margin-1,983.51%
Return on Equity-37.80%

Analyst Ratings as of 11/14/2021

Buy
1
Overweight
0
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset